clinical trial · NCT03978000
IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study
Necrotizing EnterocolitisIBP-9414Placebo
brief summary
IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the prevention of necrotizing enterocolitis.
started
Jul 4, 2019
primary completion
Jun 1, 2024
completion
Jul 1, 2024
last updated
Apr 12, 2024
official title
A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol